Sanofi Oncology And Rare Disease Updates Spark Fresh Valuation Interest [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Sanofi's Sarclisa (isatuximab) subcutaneous formulation received a positive opinion from the European Medicines Agency's CHMP for use in multiple myeloma. The US FDA granted Breakthrough Therapy designation to venglustat for the treatment of type 3 Gaucher disease. These regulatory milestones highlight progress in Sanofi's oncology and rare disease product pipeline. Sanofi (ENXTPA:SAN) is seeing fresh attention after these product updates, with the share price at €81.9 and a value score of 5. The stock is up 6.6% over the past week, while returns over 1 year and 3 years have been negative at 16.1% and 7.3% respectively, and essentially flat year to date. That mixed performance sets the backdrop for how investors might weigh the potential impact of these new developments. For shareholders or prospective investors, a central consideration is how these regulatory steps could influence Sano
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal [Yahoo! Finance]Yahoo! Finance
- Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host diseaseGlobeNewswire
- Sanofi eczema drug weighed down by mixed results, safety concerns [Yahoo! Finance]Yahoo! Finance
- Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patients [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 3/31/26 - Form 6-K
- 3/24/26 - Form 6-K
- 3/10/26 - Form 6-K
- SNY's page on the SEC website